pre-IPO PHARMA

COMPANY OVERVIEW

EpicentRx is a patient-driven oncology company developing new mechanisms of immunotherapy that work across diverse patient populations and tumor types with minimal toxicity, enabling the best-possible quality of life during treatment. Through two distinct technology platforms, each targeting a different half of the immune system, the company is developing drug candidates designed to act alone or in combination with other medicines to outsmart cancer. EpicentRx’s lead program is among a portfolio of novel drugs, derived from a class of molecules called dinitroazetidines, that downregulates CD47 – SIRPα to alter the tumor microenvironment and optimize immune response, and has been tested in several clinical trials including an ongoing Phase 3 study in small cell lung cancer. The company is also advancing multiple programs through its smart virus platform, including personalized cancer vaccines that have shown to be effective in both chemotherapy and immune resistant tumors.


LOCATION

  • La Jolla, CA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.epicentrx.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Dec 6, 2022

    EpicentRx Announces Patent Issued for Radiation Protection with RRx-001 in Combination Regimens


    Dec 23, 2021

    Proto Oncogene Protein C-MYC Inhibitors Industry 2021 Featuring Insights for 15+ Companies and Drugs, Including RRx-001 (EpicentRx) and WP1066 (Moleculin Biotech)


    Sep 29, 2021

    EpicentRx Announces Completion of First Cohort in Phase 1 "BETA PRIME" Trial with AdAPT-001


    Mar 3, 2020

    EpicentRx IND Application for Second Immuno-oncology Program, a TGF-β Trap Adenovirus, Receives FDA Clearance


    Dec 4, 2019

    EpicentRx Appoints Senior Life Science Financial Executive Dr. Franck Brinkhaus as Chief Financial Officer


    For More Press Releases


    Google Analytics Alternative